Acute Myeloid Leukemia with t(8;16)(p11.2;p13.3)/ KAT6A-CREBBP in a Patient with an NF1 Germline Mutation and Clinical Presentation Mimicking Acute Promyelocytic Leukemia.
Journal
Journal of the Association of Genetic Technologists
ISSN: 1523-7834
Titre abrégé: J Assoc Genet Technol
Pays: United States
ID NLM: 9807282
Informations de publication
Date de publication:
2020
2020
Historique:
received:
04
09
2020
accepted:
04
09
2020
entrez:
5
9
2020
pubmed:
6
9
2020
medline:
6
9
2020
Statut:
ppublish
Résumé
Acute myeloid leukemia (AML) with t(8;16)(p11.2;p13.3)/KAT6A-CREBBP is an uncommon subtype of AML accounting for less than 0.5% of AML cases. AML with t(8;16)/KAT6A-CREBBP has characteristic clinical and pathologic features including disseminated intravascular coagulation (DIC), leukemia cutis, hemophagocytosis, monocytic or myelomonocytic differentiation, is frequently associated with therapy-related AML and has a poor prognosis. We present a classic case of AML with t(8;16)/KAT6A-CREBBP occurring in a patient with both a germline NF1 mutation and recent cytotoxic therapy for embryonal rhabdomyosarcoma.
Types de publication
Journal Article
Langues
eng
Pagination
135-139Informations de copyright
Copyright© by the Association of Genetic Technologists.